| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S |
| P698 | PubMed publication ID | 10643714 |
| P2093 | author name string | Blake S | |
| Adams JL | |||
| Lee JC | |||
| Badger AM | |||
| Hoffman SJ | |||
| Boehm JC | |||
| Griswold DE | |||
| Gowen M | |||
| Rieman DJ | |||
| Stroup GB | |||
| Webb E | |||
| Kapadia R | |||
| Swift BA | |||
| P2860 | cites work | A protein kinase involved in the regulation of inflammatory cytokine biosynthesis | Q24311139 |
| Structural basis of inhibitor selectivity in MAP kinases | Q27765381 | ||
| A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells | Q28237789 | ||
| Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles | Q28242608 | ||
| A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins | Q29617438 | ||
| SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 | Q29620495 | ||
| p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials | Q33716182 | ||
| Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. | Q34323179 | ||
| Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases | Q36444013 | ||
| Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases | Q36465559 | ||
| Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis | Q37908865 | ||
| Cytokines and other mediators in rheumatoid arthritis | Q40199820 | ||
| New directions for biological therapy in rheumatoid arthritis | Q40760356 | ||
| Role of cytokines in the regulation of bone resorption | Q40798080 | ||
| Insights into the role of nitric oxide in inflammatory arthritis | Q41219868 | ||
| Biologic agents for treating rheumatoid arthritis. Concepts and progress | Q41398093 | ||
| Pyrroles and other heterocycles as inhibitors of p38 kinase | Q42537156 | ||
| Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site | Q42550034 | ||
| Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid | Q43456618 | ||
| Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059 | Q63408082 | ||
| Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides | Q68094829 | ||
| Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis | Q69049138 | ||
| Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis | Q70411071 | ||
| Microprocessor-assisted plethysmograph for the measurement of mouse paw volume | Q70785898 | ||
| 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency | Q71591889 | ||
| Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses | Q72512112 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 175-183 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis | |
| P478 | volume | 43 |
| Q34527178 | A review of crosstalk between MAPK and Wnt signals and its impact on cartilage regeneration |
| Q44962642 | Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy |
| Q53461988 | Adrenomedullin inhibits IL-1β-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production. |
| Q54500893 | Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-alpha. |
| Q36836817 | Are MAP kinases drug targets? Yes, but difficult ones |
| Q34614103 | Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). |
| Q24793013 | Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition |
| Q33774760 | Comparison of DEXA and QMR for assessing fat and lean body mass in adult rats |
| Q38749984 | Complement-induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction |
| Q35606373 | Cyclooxygenase-2 and prostaglandins in articular tissues |
| Q35594482 | Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis |
| Q36401883 | Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues |
| Q40749904 | Differentiation regulates interleukin-1beta-induced cyclo-oxygenase-2 in human articular chondrocytes: role of p38 mitogen-activated protein kinase |
| Q34907847 | Dual specificity phosphatase 1 regulates human inducible nitric oxide synthase expression by p38 MAP kinase |
| Q35083265 | Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis |
| Q37397656 | Garden of therapeutic delights: new targets in rheumatic diseases |
| Q37536881 | Hierarchical microimaging of bone structure and function |
| Q40909592 | IL-1 mediates TNF-induced osteoclastogenesis |
| Q36706331 | In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice |
| Q40693659 | Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells |
| Q73521679 | Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis |
| Q64986074 | Inhibition of Osteoclastogenesis by Thioredoxin-Interacting Protein-Derived Peptide (TN13). |
| Q35023644 | Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. |
| Q36622407 | Mitogen activated protein kinase inhibitors: where are we now and where are we going? |
| Q38078271 | Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis |
| Q37242365 | Mitogen-activated protein kinases as therapeutic targets in osteoarthritis |
| Q26852727 | Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease |
| Q37379313 | Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice. |
| Q33992822 | NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments |
| Q34585191 | Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy |
| Q34109124 | Osteoarthritis and cartilage: the role of cytokines |
| Q43214803 | P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis |
| Q24806889 | Post-transcriptional regulation of pro-inflammatory gene expression |
| Q34276030 | Potential biologic agents for treating rheumatoid arthritis |
| Q35953531 | Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis |
| Q36984884 | Primer: signal transduction in rheumatic disease--a clinician's guide |
| Q43764129 | Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity |
| Q43552118 | RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency |
| Q38841936 | Review: Long Noncoding RNAs in the Regulation of Inflammatory Pathways in Rheumatoid Arthritis and Osteoarthritis. |
| Q37348061 | Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression |
| Q79236264 | SAR of 3,4-Dihydropyrido[3,2-d]pyrimidone p38 inhibitors |
| Q94047801 | SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics |
| Q37466941 | SD0006: a potent, selective and orally available inhibitor of p38 kinase |
| Q35553538 | Signal transduction networks in rheumatoid arthritis. |
| Q35564239 | Skin involvement in dermatomyositis |
| Q34600992 | Small therapeutic molecules for the treatment of inflammatory bowel disease |
| Q40221927 | Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function |
| Q35944984 | Spinal p38 MAP kinase regulates peripheral cholinergic outflow |
| Q40602779 | Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. |
| Q43553881 | Synthesis and biological activity of the structural analogues of (-)-cabenegrin A-I. |
| Q39850143 | The Future of ANCA-associated Vasculitis |
| Q35046269 | The anti-inflammatory carbazole, LCY-2-CHO, inhibits lipopolysaccharide-induced inflammatory mediator expression through inhibition of the p38 mitogen-activated protein kinase signaling pathway in macrophages. |
| Q43542785 | The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy |
| Q38404632 | The involvement of the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute inflammation in vivo |
| Q34601353 | The mitogen-activated protein kinase p38α regulates tubular damage in murine anti-glomerular basement membrane nephritis |
| Q36934993 | The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis |
| Q40660116 | The p38 mitogen-activated protein kinase regulates interleukin-1beta-induced IL-8 expression via an effect on the IL-8 promoter in intestinal epithelial cells. |
| Q36423252 | The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells |
| Q24806147 | Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors |
| Q34276023 | Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis |
| Q24812465 | Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo |
| Q36217233 | Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis |
| Q34721995 | Whole Genome Expression Profiling and Signal Pathway Screening of MSCs in Ankylosing Spondylitis. |
| Q34483284 | p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. |
| Q35209995 | p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases |
| Q33624820 | p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice |
| Q81573121 | p38 mitogen-activated protein kinase-dependent chemokine production, leukocyte recruitment, and hepatocellular apoptosis in endotoxemic liver injury |
Search more.